ELYM News and Press, Eliem Therapeutics Inc

2024-07-12 16:29:24 ET More on Eliem Therapeutics Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value Financial information for Eliem Therapeutics Read the full article on Seeking Alpha For further details see: Eliem Therapeut...

2024-06-28 13:58:26 ET Summary Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 mil...

2024-06-28 07:27:11 ET More on Eliem Therapeutics Eliem Therapeutics to buy Tenet, announces $120 million private placement Financial information for Eliem Therapeutics Read the full article on Seeking Alpha For further details see: Eliem Therapeutics to ...

SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc . (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitutio...

Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy Post-close cash and cash equivalents of $220 million expected to fund operations i...

2024-06-17 07:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-17 03:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-15 13:53:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eliem Therapeutics (NASDAQ: ELYM ) just reported results for the first quarter of 2024. Eliem Therapeutics reported earnings per share of -6 cents. The company did not...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-03 12:51:44 ET Gainers: Beneficient BENF +355% . Safe & Green Holdings Corp SGBX +129% . NFT Ltd. MI +39% . Smart for Life ( SMFL ) +42% . AERWINS Technologies ( AWIN ) +27% . Arteris AIP +33% . Upland Software UPLD ...